Please assess the completion status of the following clinical trial:

Trial Title: THINC-it Vortioxetine - Sensitivity to Change

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
MDD Population~Inclusion Criteria:~1. The participant is able and willing to provide informed consent.~2. The participant is male or female 18-65 years of age.~3. The participant has received a current diagnosis of a major depressive episode (MDE) as part of MDD as per DSM-5 criteria.~4. The participant's current MDE is confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I 5.0.).~5. The participant is an outpatient of a psychiatric setting.~6. The participant has a MADRS score ≥ 26 at screening and baseline.~7. The participant's reported duration of the current MDE is at least 3 months.~8. At least one prior major depressive episode validated by previous treatment (e.g., guideline-informed pharmacotherapy and/or manual-based psychotherapy).~9. All participants will be screened for cognitive impairment based on DSST performance (pen-and-paper version) with a maximum baseline score of 70 correct symbols entered to avoid ceiling effects.~Exclusion Criteria:~1. Current alcohol and/or substance use disorder.~2. Presence of comorbid psychiatric disorder other than MDD that is a focus of clinical concern as confirmed by the M.I.N.I 5.0.~3. Medications approved and/or employed off-label for cognitive dysfunction (e.g., psychostimulants).~4. Any medication for a general medical disorder that, in the opinion of the investigator, may affect cognitive function (e.g., corticosteroids, beta-blockers).~5. Use of benzodiazepines within 12 hours of cognitive assessments.~6. Consumption of alcohol within 8 hours of cognitive assessments.~7. Recent use of marijuana as determined by a toxicology screen.~8. Physical, cognitive, or language impairments sufficient to adversely affect data derived from cognitive assessments.~9. Diagnosis reading disability or dyslexia.~10. Clinically significant learning disorder by history.~11. Electroconvulsive therapy (ECT) in the last 6 months.~12. History of moderate or severe head trauma (e.g., loss of consciousness for \>1 hour), other neurological disorders, or unstable systemic medical diseases that in the opinion of the investigator are likely to affect the central nervous system.~13. Pregnant and/or breastfeeding.~14. Received investigational agents as part of a separate study within 30 days of the screening visit.~15. Actively suicidal or evaluated as being a suicide risk (a score of \> 4 on the MADRS and/or per clinical judgment using the Columbia-Suicide Severity Rating Scale).~16. Currently receiving treatment with Monoamine Oxidase Inhibitors (MAOIs) anti-depressants, antibiotics such as linezolid, or intravenous methylene blue.~Healthy Control Population~Inclusion Criteria:~1. No current or past history of mental disorder as evidenced by the M.I.N.I. 5.0 for DSM-IV.~2. No first-degree relative with an established diagnosis by a healthcare provider of a mood or psychiatric disorder.~3. No unstable medical disorders.~Exclusion Criteria:~1. Use of any medication for a general medical disorder and/or condition that, in the opinion of the investigator, may affect cognitive function (e.g., corticosteroids, beta-blockers).~2. Pregnant and/or breastfeeding.~3. Consumption of alcohol within 8 hours of THINC-it tool administration.~4. Recent use of marijuana as determined by a toxicology screen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Major Depressive Disorder Population (Type: EXPERIMENTAL): 100 Individuals with DSM-5-defined MDD, aged 18-65~All participants receiving vortioxetine for a total of 8 weeks. Participants will receive10 mg/day on days 1-14 of the study treatment period, with the option to increase to vortioxetine 20 mg/day at the end of Week 2 based on physician's judgment. For the remaining 6 weeks, the dose of vortioxetine will be flexible at 10 or 20 mg/day as decided by a research doctor.~Patients will receive the THINC-it over 3 time frame periods. The THINC-it comprised of: Spotter, Symbol Check, Codebreaker, Trails, and PDQ-5-D.
- Healthy Control Population (Type: OTHER): 50 Healthy Controls (18-65 years of age) matched on sex, age, and years of education

Based on this trial design, predict the completion outcome and termination type (if applicable).